- HC Wainwright & Co. assumed coverage of Agios Pharmaceuticals.
- The rating is Buy.
- The report was published via Benzinga.
HC Wainwright & Co. initiated coverage of Agios Pharmaceuticals with a Buy rating. The move signals a positive view on the biotech stock.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.